Screening DNA Stool Test for Colorectal Cancer

CMS proposes not to expand the colorectal cancer screening benefit to include coverage of PreGen-Plus, a commercially available screening DNA stool test.

The FDA determines that this test requires pre-market review and approval. A subsequent request for reconsideration will be considered once FDA approval is obtained.